How can health innovations be financed and scaled without allowing profit or speed to overtake safety, access, and patient benefit?
This trio examines the development, financing, regulation, distribution, and adoption of health innovation. Innovation creates interventions, technologies, treatments, and diagnostic capabilities. Business organizes investment, production, ownership, distribution, and scale. Health establishes the standards of safety, efficacy, access, and patient benefit. The trio cannot be reduced to Health × Innovation because a medical invention may exist without reaching patients. It cannot be reduced to Business × Innovation because commercial success does not establish health value. Business × Health does not explain the creation of new capabilities.
Each element is indispensable to the system through which health technologies are created, financed, evaluated, and distributed.
Constructive expressions include pharmaceutical development, biotechnology, medical devices, digital health, diagnostics, and scalable systems that expand access to effective care.
Imbalances include unaffordable medicine, rushed products, exploitative use of health data, patent barriers, unequal access, and investment directed toward profitable rather than urgent health needs.